







an Open Access Journal by MDPI

# **B and T Cell-Mediated Immunity 2.0**

Guest Editors:

## Dr. Monica A. McArthur

Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA

## Dr. Franklin Toapanta

Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Deadline for manuscript submissions:

closed (30 June 2022)

## **Message from the Guest Editors**

Dear Colleagues,

Generation of vigorous cell-mediated immune responses is critical to protection against many infectious diseases. T cells and B cells represent separate but interconnected arms of the adaptive immune response. As such, they are critical in providing long-lasting protection, thanks to the induction of immune memory, following vaccination or natural infection. This Special Issue focuses on T and B cellmediated immunity as they relate to vaccination and protection against infectious diseases. The goal is to enhance our knowledge of the important roles that T and B long-lasting provide cells plav to protection. Understanding the contributions of T and B cells, as well as their interactions, following vaccination and/or natural infection could provide critical insights that will help further vaccine development.

Dr. Monica A. McArthur Dr. Franklin Toapanta Guest Editors







IMPACT FACTOR 7.8





an Open Access Journal by MDPI

## **Editor-in-Chief**

### Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

## **Message from the Editor-in-Chief**

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

#### **Author Benefits**

**Open Access:** free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## **Contact Us**